GlassScriptPhysician profile
John Emmanuel Markantonis
NPI 1720527864
$1,088.67
in general payments reported to CMS, 2019-2025
8 companies · $847 in 2025
The $847 reported for 2025 was more than what 88% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $35.86 · 2024: $88.15 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.39 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $423.31 | 2025 | |
| Merck Sharp & Dohme LLC | $150.70 | 2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $128.25 | 2025 | Zevtera |
| Abbvie INC. | $124.94 | 2025 | |
| Viiv Healthcare Company | $117.58 | 2022 | |
| Melinta Therapeutics, LLC | $74.70 | 2024 | Rezzayo |
| Shionogi INC | $51.50 | 2023-2025 | Fetroja |
| Roche Diagnostics Corporation | $17.69 | 2023 | Pathway Anti-Her-2/Neu (4b5) Rabbit Monoclonal Primary Antibody |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Markantonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.